SELLAS Life Sciences Group, Inc. (SLS) Dividend History

SELLAS Life Sciences Group, Inc. (SLS) is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer. The company's portfolio includes treatments designed to enhance the immune system's ability to recognize and destroy cancer cells, with an emphasis on innovative approaches to immuno-oncology. SELLAS aims to address unmet medical needs through its research-driven pipeline and strategic collaborations.

7 Times Square, New York, NY, 10036
Phone: (646) 200-5278
Website: https://www.sellaslifesciences.com

Dividend History

Pay Date	Amount	Ex Dividend Date	Record Date
April 05, 2011	$0.24	03/24/2011	03/28/2011
December 20, 2010	$0.42	12/09/2010	12/13/2010
September 22, 2010	$0.15	09/09/2010	09/13/2010
June 21, 2010	$0.09	06/10/2010	06/14/2010
March 29, 2010	$0.09	03/18/2010	03/22/2010
December 21, 2009	$0.36	12/10/2009	12/14/2009
September 24, 2009	$0.06	09/10/2009	09/14/2009
June 09, 2009	$0.13	05/28/2009	06/01/2009
March 23, 2009	$0.13	03/12/2009	03/16/2009
December 22, 2008	$0.44	12/11/2008	12/15/2008
September 22, 2008	$0.44	09/11/2008	09/15/2008

Dividends Summary

SELLAS Life Sciences Group, Inc. has issued 11 dividend payments over the past 3 years
The most recent dividend was paid 5177 days ago, on April 5, 2011
The first recorded dividend was paid on September 22, 2008
The highest dividend payout was $0.44 per share
The average dividend over this 3 year span is $0.23 per share
SELLAS Life Sciences Group, Inc. has decreased its dividend payments by 45.07% since 2008

Company News

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

SELLAS presented preclinical data showing that its CDK9 inhibitor SLS009 demonstrated potent anti-proliferative activity in ASXL1 mutant colorectal cancer cell lines, suggesting its potential as a targeted therapy for this patient population.

GlobeNewswire Inc.
Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight

The blood cancer market is experiencing robust growth, driven by rising incidence rates and advancements in targeted therapies and immuno-oncology. Increasing adoption of CAR-T cell therapies, monoclonal antibodies, and personalized medicine is transforming treatment outcomes.

GlobeNewswire Inc.

Featured Companies: ABBV ACLX ADCT BMY JNJ KROS MRK REGN
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025

The article discusses recent advancements in cancer research and treatment, including promising results from clinical trials of various cancer therapies developed by companies like Oncolytics Biotech, Celcuity, Genenta Science, Sellas Life Sciences, and Amgen.

Benzinga

Featured Companies: AMGN CELC ONCY
SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024

SELLAS Life Sciences announced that data from its Phase 2a trial of SLS009, a CDK9 inhibitor, in relapsed/refractory acute myeloid leukemia will be presented at the 2024 ASH meeting. The trial showed promising safety and efficacy results, with a 50% response rate at the selected dose level.

GlobeNewswire Inc.
SELLAS Announces U.S. FDA Rare Pediatric Disease - GlobeNewswire

SELLAS Life Sciences Group, Inc. announced that the U.S. FDA has granted Rare Pediatric Disease Designation to its drug SLS009 for the treatment of pediatric acute myeloid leukemia, a serious and life-threatening disease with limited treatment options.

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 05:02:54 UTC